Figure 5.
Ang-2 serum levels of patients at the third cycle of chemotherapy. (A) Ang-2 serum levels of NSCLC patients who received PBC in combination with anti-VEGF before treatment and after the third cycle of chemotherapy. (B) Ang-2 serum levels of SCLC patients who received PBC before treatment and after the third cycle of chemotherapy.
